Bicycle Therapeutics (NASDAQ:BCYC) Reaches New 1-Year Low – Should You Sell?

Bicycle Therapeutics plc (NASDAQ:BCYC)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $9.41 and last traded at $9.89, with a volume of 629111 shares trading hands. The stock had previously closed at $9.63.

Analysts Set New Price Targets

Several research analysts have recently commented on BCYC shares. Stephens reiterated an “equal weight” rating and set a $15.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. B. Riley lowered their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. JMP Securities reduced their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research report on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Stock Down 1.3 %

The stock has a market capitalization of $655.94 million, a PE ratio of -2.95 and a beta of 1.12. The firm has a 50 day moving average price of $12.33 and a 200 day moving average price of $18.40.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10. The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s revenue was down 30.2% on a year-over-year basis. During the same period last year, the business posted ($1.16) earnings per share. On average, equities analysts forecast that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Insider Activity at Bicycle Therapeutics

In other news, insider Santiago Arroyo sold 4,943 shares of Bicycle Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the transaction, the insider now owns 69,057 shares in the company, valued at approximately $973,013.13. The trade was a 6.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Lee sold 9,038 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at approximately $6,974,916.34. The trade was a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 27,677 shares of company stock valued at $392,413. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the stock. Assetmark Inc. bought a new position in Bicycle Therapeutics in the 3rd quarter valued at approximately $34,000. Barclays PLC increased its stake in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after purchasing an additional 2,345 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Bicycle Therapeutics in the 4th quarter worth $57,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Bicycle Therapeutics by 30.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after purchasing an additional 2,191 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.